One of the largest individual investments in the company's history: pharmaceutical service provider Vetter Pharma is building a new site in Saarland

Aerial view of the 40-hectare construction site (marked) acquired by Vetter in Saarlouis for the new production facility. © Vetter Pharma International GmbH

Anke Rehlinger, Minister President of Saarland, and Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the Vetter family ownership, with the model for the new, multi-stage production site in Saarlouis. (Image source: State Chancellery of Saarland / Jennifer Weyland)

– Initial investment volume in Saarlouis of 480 million euros
– Construction start in the second quarter of 2026
– Production of medications planned to start in 2031

Vetter, one of the world's leading pharmaceutical service providers for the manufacturing of injectable medicines, confirms during a meeting with the Saarland state government at the State Chancellery its construction project for a new, state-of-the-art production facility in Saarlouis. This underscores the family company's long-term growth strategy and its commitment to the German location. The construction start is planned for the second quarter of 2026. An investment volume of nearly half a billion euros is planned for the first phase of the production plant. The site is scheduled to be operational in 2031.

By the end of 2024, Vetter had acquired the approximately 40-hectare industrial site in Saarlouis. The decision to settle in Saarland is based on long-term strategic considerations and convincing location factors. The European Commission has approved state aid of up to 47 million euros for the extensive construction project. In the long term, Vetter envisions the potential creation of up to 2,000 jobs at the site. Recruitment will begin as soon as the structural prerequisites are in place. Open positions will then be posted on the Vetter website.

“With the construction of our new production facility in Saarlouis, we are taking an important milestone on our sustainable growth path. Long-term success is achieved through the right balance between stability and targeted expansion,” emphasizes Senator h.c. Udo J. Vetter, Chairman of the Supervisory Board and member of the family owners. “We have great confidence in Saarland and are proud to strengthen the economic location of Germany with our investments. At the same time, we reaffirm our long-term commitment as a family business in the global pharmaceutical market – including our ongoing investments in the USA.”

The Saarland state government also welcomes this decision. “We are pleased with Vetter's decision to establish Saarlouis as a new production site. This is a strong signal for the future of Saarland and a success of the settlement efforts,” said Saarland Prime Minister Anke Rehlinger. Economy Minister Jürgen Barke added: “The planned investment means diversification of our economy and creates new jobs in a market with a future. This strengthens Saarland in the structural change and contributes to the sustainable development of our innovation and industrial landscape.”

For over 75 years, Vetter has stood for quality, innovation, and responsibility in pharmaceutical production, helping patients worldwide achieve a better quality of life. To meet the growing demand and increasing market requirements, the company is strategically investing in its existing locations in Germany, Austria, and the USA. With the new site in Saarlouis, Vetter is further significantly expanding its production capacity.